Drug Approval | February 14, 2022
Zydus gets 180 days of shared exclusivity for Roflumilast tablets
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
This is the fourth facility from the company to receive this registration
The group now has 324 approvals and has so far filed over 400 ANDAs
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Subscribe To Our Newsletter & Stay Updated
